The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI

Completed

Conditions studied: Pulmonary Arterial Hypertension

In brief

Explore the impact of drug candidate CS1 on pathological vascular remodeling of small pulmonary arteries in the disease pulmonary arterial hypertension (PAH). This sub-study for CS1-004 aims to utilize FRI, an innovative, non-invasive imaging technology to visualize how long-term use of CS1 influences structural changes in pulmonary arteries. This sub-study seeks to provide valuable insights into the potential of CS1 to transform PAH treatment in some patients enrolled in the Expanded Access Program (CS1-004).

Key facts

Study ID

NCT06907693

Run by

Prisma Health-Upstate

People needed

7

Starts

2025-03-14

Expected to finish

2026-04-09

Last updated by the study team

2026-04-13

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participation in the CS1-004 clinical trial

You may not qualify if…

• Inability to undergo a CT pulmonary angiography scan (i.e., claustrophobia)
• Individuals who are pregnant or who become pregnant during the sub-study
• eGFR <30 mL/min/1.73m2 as calculated by Modification of Diet in Renal Disease (MDRD)
• Allergy to Iodine contrast agents

Where it is running

• Prisma Health — Greenville, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.